New drug combo aims to tame Tough-to-Treat blood cancer
NCT ID NCT05199051
Summary
This study is testing a combination of three drugs—gemtuzumab ozogamicin, cytarabine, and gilteritinib—for adults with a specific type of acute myeloid leukemia (AML) that has a FLT3 mutation and has come back or not responded to prior treatment. The main goals are to see if the combination is safe and if it helps patients live longer without their cancer getting worse. The study is for 19 adults in France whose cancer has specific genetic markers and who meet strict health criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHMS de Chambery
Chambéry, France
-
CHRU Nancy
Nancy, France
-
CHU Bordeaux
Bordeaux, France
-
CHU Limoges
Limoges, France
-
CHU d'Amiens
Amiens, France
-
CHU d'Angers
Angers, France
-
CHU de Caen
Caen, France
-
Centre Henri Becquerel
Rouen, France
-
Centre Hospitalier Universitaire de Nice
Nice, France
-
Centre Hospitalier de Versailles
Versailles, France
-
HIA Percy
Clamart, France
-
Hôpital Saint Louis
Paris, France
Conditions
Explore the condition pages connected to this study.